Phase 2
N=68
Academic Stress and Proinflammatory Cytokines: Omega-3 Intervention
Stress-related Changes in Inflammation
Bottom Line
View on ClinicalTrials.gov: NCT00519779 ↗Enrolled (actual)
68
Serious AEs
0.0%
Results posted
Mar 2012
Primary outcome: Primary: Serum ln(IL-6) — 0.054; 0.051 ln(pg/mL) — p=0.97
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- omega-3 supplementation (Dietary_supplement); Oral omega-3 fish oil placebo (Dietary_supplement)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- Primary completion
- Dec 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serum ln(IL-6) |
0.054; 0.051 | 0.97 |
| PRIMARY Serum ln(TNF-a) |
0.61; 0.54 | 0.06 |
| PRIMARY Stimulated ln(IL-6) |
11.1; 10.9 | 0.04 sig |
| PRIMARY Stimulated ln(TNF-alpha) |
7.4; 7.3 | 0.08 |
| SECONDARY ln(Beck Anxiety Score) |
1.2; 0.93 | 0.04 sig |
| SECONDARY ln(CES-D) |
1.6; 1.6 | 0.93 |
Summary
This study is designed to examine the effects of fish oil on immune function and mood in medical students.
Eligibility Criteria
Inclusion Criteria
- OSU preclinical medical or dental student, or graduate nursing student
- male or female
Exclusion Criteria
- taking certain medications with immune or endocrine effects
- chronic health conditions
- smoking
- excessive use of alcohol or caffeine
- significant digestive problems
- routine use of fish oil or flaxseed supplements or high fish intake
- fish allergy
Data sourced from ClinicalTrials.gov (NCT00519779). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.